Phaseline

Companies › Nexcella

Nexcella: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NXC-201 CAR-T
anti-BCMA CAR-T cell therapy
BCMAPhase 1Light Chain (AL) AmyloidosisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06097832NXC-201 CAR-TPhase 1Light Chain (AL) AmyloidosisMetabolic and endocrineDec 2026

Targets

BCMA (1)

Companies with the same targets

iCell Gene Therapeutics AbbVie Chongqing Precision Biotech Poseida Therapeutics Regeneron Pharmaceuticals Johnson & Johnson (Janssen) AstraZeneca Lakefront Biotherapeutics West Gracell Biotechnologies (Shanghai) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.